NASDAQ: CASI | 中文 | Contact Us


CASI Hosts Nobel Laureate James P. Allison

September 10, 2019

CASI hosts a key opinion leader (KOL) symposium addressing innovations in cancer immunotherapy. A replay of Nobel Laureate James P. Allison Discussion on Immunotherapy Checkpoint Blockade in Cancer Therapy can be found at

Evomela Commercially Available In China

August 12, 2019

EVOMELA® received market approval by the China National Medical Products Administration (NMPA) for use as high-dose conditioning treatment prior to hematopoietic progenitor (stem) cell transplant in patients with multiple myeloma, and as a palliative treatment of patients with multiple myeloma for whom oral therapy is not appropriate. It is the only approved and commercially available melphalan product in China.

U.S. FDA-Approved Products In-Licensed for the Greater China Region


Multiple Myeloma


Non-Hodgkin's Lymphoma


Acute Lymphoblastic Leukemia

Pre-Clinical Candidates


Multiple Myeloma


Hematological Malignancies
Learn more about our product pipeline

About Us

CASI is a U.S. NASDAQ-listed biopharmaceutical company with a platform to develop and accelerate the launch of pharmaceutical products and innovative therapeutics in China, the U.S., and throughout the world. We have offices in Rockville, Maryland, and a wholly owned subsidiary in Beijing, China, through which substantially all of our operations are conducted.

Learn More